Search the GHTC website

Global health R&D delivers for Iowa

US government investment in global health R&D has delivered

Amount
$109.8 million
to Iowa research institutions
Jobs
1,300+ new jobs
for Iowa
Iowa's top USG-funded global health R&D institutions

Iowa's top USG-funded global health R&D institutions

University of Iowa
$69.5 million
Iowa State University
$37.3 million
NeoVaxSyn Inc.
$1.4 million
Aptalogic Inc.
$574 thousand
NewLink Genetics*
$496 thousand
PathoVacs
$394 thousand
Superior Statistical Research LLC
$260 thousand

Iowa's top areas of global health R&D by USG funding

8.5%
Other coronaviruses (including MERS, SARS)
2.3%
Cryptococcal meningitis
5.8%
Flioviral diseases (including Ebola, Marburg)
11.7%
HIV/AIDS
17.7%
Malaria
25.6%
Neglected tropical diseases
Dengue
Helminth infections (Worms & Flukes)
Kinetoplastid diseases
Mycetoma
4.5%
Reproductive health
8.1%
Salmonella infections
6.3%
Tuberculosis
9.5%
Other
Bacterial pneumonia & meningitis
Chikungunya
COVID-19
Diarrheal diseases
Hepatitis C
Multi-disease/health area R&D
Zika
Global health R&D at work in Iowa

Iowa State University (ISU) researchers are looking for solutions to combat parasitic worms and the diseases they cause. ISU scientists are part of an international research team that sequenced the genomes of 81 worm species, including 45 that had never been sequenced before, to identify gene families associated with their critical functions. Parasitic worms are responsible for neglected tropical diseases such as hookworm, river blindness, and schistosomiasis, which are a significant source of illness in poor communities worldwide that lack access to clean drinking water and adequate sanitation. By examining the worms’ genomes, the team hopes to identify areas of vulnerability that could be targeted with new drug treatments.

Footnotes
  • Methodology
  • US government global health R&D investment (total to state, top funded institutions, top health areas): Authors’ analysis of USG investment data from the G-FINDER survey following identification of state location of funding recipients. Reflects funding for basic research and product development for neglected diseases from 2007 to 2022, for emerging infectious diseases from 2014–2022, and sexual and reproductive health issues from 2018 to 2022. Funding to US government agencies reflects self-funding and/or transfers from other agencies. Some industry data is anonymized and aggregated. See methodology for additional details.
  • *Organization appears to be closed/out of business.
  • Jobs created: Based on author’s analysis described above and previous analysis assessing jobs created per state from US National Institutes of Health funding. See methodology for additional details.
  • Neglected and emerging diseases: Reflects US Centers for Disease Control and Prevention data for: Chikungunya virus cases 2014–2022, Dengue virus infection cases 2010-2021, HIV diagnoses 2008–2022, Malaria cases 2007–2022, Mpox cases 2022–March 29, 2023, Tuberculosis cases 2007–2021, Viral hemorrhagic fever cases 2007-2022, and Zika virus disease cases 2015–2021.
  • Case study photo: RTI Fights NTDS